Marker Therapeutics, Inc.
NASDAQ: MRKR0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Juan F. Vera
- Employees
- 5
- Headquarters
- Houston, United States
- IPO year
- 2002
- Market cap
- $14.1M
- Website
- https://www.markertherapeutics.com
Loading MRKR…
Loading profile data…Frequently asked questions about MRKR
What does Marker Therapeutics, Inc. (MRKR) do?
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on discovering and bringing to market a variety of T cell-based immunotherapies and peptide-based vaccines. These cutting-edge treatments are engineered to address both blood cancers (hematological malignancies) and solid tumor conditions across the United States. A co...
Where does MRKR trade?
Marker Therapeutics, Inc. (MRKR) trades on the NASDAQ Capital Market.
What sector is MRKR in?
Marker Therapeutics, Inc. (MRKR) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Marker Therapeutics, Inc.?
Juan F. Vera is the chief executive officer of Marker Therapeutics, Inc. (MRKR).
Where is Marker Therapeutics, Inc. headquartered?
Marker Therapeutics, Inc. is headquartered in United States.
Does MRKR pay a dividend?
Marker Therapeutics, Inc. (MRKR) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MRKR go public?
Marker Therapeutics, Inc. (MRKR) completed its initial public offering in 2002.